NCT07033585: An ongoing trial by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
This trial is ongoing. It must report results 1 year, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07033585 |
|---|---|
| Title | Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 15, 2025 |
| Completion date | Oct. 18, 2026 |
| Required reporting date | Oct. 18, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |